Janne T Backman

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 17

Top Topics

Antiplatelet Therapy

Cancer Stem Cells

Clinical Decision Support

Top Venues

Clinical pharmacology and therapeutics

Clinical and translational science

Drug metabolism and disposition: the biological fate of chemicals

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Kreetta Hämäläinen, Päivi Hirvensalo, Mikko Neuvonen, Aleksi Tornio, Janne T Backman, Marko Lehtonen, Mikko Niemi
Non-targeted metabolomics for the identification of plasma metabolites associated with organic anion transporting polypeptide 1B1 function. Clinical and translational science 17 (3) (2024)
Anssi J H Mykkänen, E Katriina Tarkiainen, Suvi Taskinen, Mikko Neuvonen, Maria Paile-Hyvärinen, Tuomas Olavi Lilius, Tuija Tapaninen, Kathrin Klein, Matthias Schwab, Janne T Backman, Aleksi Tornio, Mikko Niemi
Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP. Clinical pharmacology and therapeutics 115 (6) (2024)
Kreetta Hämäläinen, Päivi Hirvensalo, Mikko Neuvonen, Aleksi Tornio, Janne T Backman, Marko Lehtonen, Mikko Niemi
Non-targeted metabolomics for the identification of plasma metabolites associated with organic anion transporting polypeptide 1B1 function. Clinical and translational science 17 (3) (2024)
Anssi J H Mykkänen, E Katriina Tarkiainen, Suvi Taskinen, Mikko Neuvonen, Maria Paile-Hyvärinen, Tuomas Olavi Lilius, Tuija Tapaninen, Kathrin Klein, Matthias Schwab, Janne T Backman, Aleksi Tornio, Mikko Niemi
Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP. Clinical pharmacology and therapeutics 115 (6) (2024)
Anssi J H Mykkänen, E Katriina Tarkiainen, Suvi Taskinen, Mikko Neuvonen, Maria Paile-Hyvärinen, Tuomas Olavi Lilius, Tuija Tapaninen, Kathrin Klein, Matthias Schwab, Janne T Backman, Aleksi Tornio, Mikko Niemi
Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP. Clinical pharmacology and therapeutics (2024)
Minna Lehtisalo, E Katriina Tarkiainen, Mikko Neuvonen, Mikko Holmberg, Johanna I Kiiski, Outi Lapatto-Reiniluoto, Anne M Filppula, Mika Kurkela, Janne T Backman, Mikko Niemi
Ticagrelor increases exposure to the breast cancer resistance protein substrate rosuvastatin. Clinical pharmacology and therapeutics (2023)
Aleksi M Olkkola, Tuija Tapaninen, Aleksi Tornio, Milka Hauta-Aho, Outi Lapatto-Reiniluoto, Mikko Neuvonen, Johanna I Kiiski, Pertti J Neuvonen, Mikko Niemi, Janne T Backman
Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment. British journal of clinical pharmacology (2023)
Anssi J H Mykkänen, Suvi Taskinen, Mikko Neuvonen, Maria Paile-Hyvärinen, E Katriina Tarkiainen, Tuomas Olavi Lilius, Tuija Tapaninen, Janne T Backman, Aleksi Tornio, Mikko Niemi
Genomewide Association Study of Simvastatin Pharmacokinetics. Clinical pharmacology and therapeutics 112 (3) (2022)
Minna Lehtisalo, Suvi Taskinen, E Katriina Tarkiainen, Mikko Neuvonen, Jenni Viinamäki, Maria Paile-Hyvärinen, Tuomas Olavi Lilius, Tuija Tapaninen, Janne T Backman, Aleksi Tornio, Mikko Niemi
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics. British journal of clinical pharmacology (2022)
Aleksi Tornio, Anne M Filppula, Janne T Backman
Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel. Basic & clinical pharmacology & toxicology (2021)
Päivi Hirvensalo, Aleksi Tornio, Tuija Tapaninen, Maria Paile-Hyvärinen, Mikko Neuvonen, Janne T Backman, Mikko Niemi
Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. Clinical and translational science (2021)
Päivi Hirvensalo, Aleksi Tornio, Terhi Launiainen, Maria Paile-Hyvärinen, Tuija Tapaninen, Mikko Neuvonen, Janne T Backman, Mikko Niemi
UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study. Clinical pharmacology and therapeutics 108 (4) (2020)
Matti K Itkonen, Aleksi Tornio, Mikko Neuvonen, Pertti J Neuvonen, Mikko Niemi, Janne T Backman
Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. Drug metabolism and disposition: the biological fate of chemicals 47 (4) (2019)
Helinä Kahma, Anne M Filppula, Terhi Launiainen, Jenni Viinamäki, Mikko Neuvonen, Eric A Evangelista, Rheem A Totah, Janne T Backman
Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8. Drug metabolism and disposition: the biological fate of chemicals 47 (4) (2019)
Tuija Tapaninen, Aleksi M Olkkola, Aleksi Tornio, Mikko Neuvonen, Erkki Elonen, Pertti J Neuvonen, Mikko Niemi, Janne T Backman
Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction. Clinical and translational science 13 (2) (2019)
Päivi Hirvensalo, Aleksi Tornio, Mikko Neuvonen, Wilma Kiander, Heidi Kidron, Maria Paile-Hyvärinen, Tuija Tapaninen, Janne T Backman, Mikko Niemi
Enantiospecific Pharmacogenomics of Fluvastatin. Clinical pharmacology and therapeutics 106 (3) (2019)
Helinä Kahma, Anne M Filppula, Mikko Neuvonen, E Katriina Tarkiainen, Aleksi Tornio, Mikko T Holmberg, Matti K Itkonen, Moshe Finel, Pertti J Neuvonen, Mikko Niemi, Janne T Backman
Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . Drug metabolism and disposition: the biological fate of chemicals 46 (2) (2017)